ClinicalTrials.gg
RecruitingNCT07236541Updated Nov 19, 2025

Impact of Airway Mucus Plugs on Secondary Pulmonary Fibrosis in COPD Patients: A Single-Center Case-Control Study

An observational study in Lung Fibrosis, sponsored by Ming Zhong. Recruiting at 1 site in China. Open to participants aged 18 Years to 89 Years. Per ClinicalTrials.gov, last updated 2025-11-19.

Sponsored by Ming Zhong · Observational

How we know

From the registry’s dates

  • Primary completion was expected by Jun 2026, 4 months ago, but the record still lists the study as recruiting.
  • Started Oct 2025; still recruiting 1 year later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Case-control
Time perspective
Prospective
Enrollment
20
Ages
18 Years to 89 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 40 studies in Pulmonary Fibrosis with a site in China — 14 open to participants now, 18 under way, 4 of them phase 3. Pulmonary Fibrosis · China.

Planned enrollment
10th of 10
20 · median 200
Started
2025
with 4 others
Observational
10 of 40
5 open now
Primary completion
2026-06
later than 5 of 17 live
Registered
35th of 40
by date

Among the 40 studies in Pulmonary Fibrosis with a site in China, this one is the 10th largest by planned enrollment of the 10 observational ones that give a count, is one of 5 that started in 2025, is one of 10 observational ones, reaches primary completion later than 5 of the 17 other live ones, and was the 35th registered.

Pulmonary Fibrosis

342 studies on the registry are indexed under Pulmonary Fibrosis; 98 are open to participants now.

Browse Pulmonary Fibrosis studies →

Open to participants now

14 of the 40 studies in Pulmonary Fibrosis with a site in China are open now. Recruiting first, the newest first:

8 more — sign in →

All 14 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 71 Pulmonary Fibrosis studies recruiting now, 41 (58%) set no upper age limit and 4 (6%) stop at 75 or younger; 8 take children under 18; 12 take healthy volunteers.

This study: 18 Years to 89 Years · all sexes.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 40 studies in Pulmonary Fibrosis with a site in China, or all of them as a file.
02

Study summary

Chronic obstructive pulmonary disease (COPD) is frequently accompanied by airway mucus plugs, which are closely associated with airflow obstruction, acute exacerbations, and increased mortality. However, whether mucus plugs contribute to secondary pulmonary fibrosis remains unclear. This single-center, prospective, case-control study aims to investigate the relationship between airway mucus plugs and lung fibrosis in patients with COPD undergoing lung cancer surgery.

During surgery, distal non-tumorous lung tissues and airway mucus will be collected for histological and molecular analyses. Mucus plug burden will be quantified using AB-PAS staining, and fibrosis will be assessed using Masson staining. Expression of epithelial-mesenchymal transition (EMT) markers, fibrotic markers, and the mechanosensitive ion channel Piezo1 will also be measured. COPD patients (FEV₁/FVC \<0.70) will be compared with non-COPD surgical controls.

The study aims to clarify whether mucus plugs are associated with increased fibrosis and to explore the potential involvement of mechanical-signaling pathways, including Piezo1 activation. Findings may provide new clinical and pathological evidence for mucus-induced fibrotic remodeling in COPD and help identify novel therapeutic targets.

03

Conditions studied

  • Lung Fibrosis

Browse trials for

04

Who can participate

Ages eligible
18 Years to 89 Years
Sexes eligible
All
Sampling method
Non-probability sample

Study population

The study population consists of adult patients undergoing lung cancer surgery at Zhongshan Hospital, Fudan University. Participants include two groups: (1) patients with chronic obstructive pulmonary disease (COPD), defined by a pre-operative post-bronchodilator FEV₁/FVC \<0.70; and (2) non-COPD surgical controls with normal lung function. During clinically indicated lung cancer resection, distal non-tumorous lung tissue samples and airway mucus (if present) are collected without adding any additional surgical risk. All participants are ≥18 years old and able to provide informed consent.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • ① Age ≥ 18 years old;

    • Planned radical resection for lung cancer, with postoperative pathological diagnosis of primary lung cancer;

      • During surgery, non tumor lung tissue at a distance of ≥ 5 cm from the tumor edge can be obtained; ④ Case group: Preoperative pulmonary function examination confirmed diagnosis of (FEV ₁/FVC\<0.70); ⑤ Control group: Preoperative lung function was normal (FEV ₁/FVC ≥ 0.70), with no history of COPD; ⑥ The subjects are able to understand and sign the form

Exclusion criteria

Exclusion Criteria:

  • ① Clear presence of other interstitial lung diseases (ILD) or idiopathic pulmonary fibrosis before or during surgery (IPF)、 Fibrosis after pneumoconiosis or tuberculosis;

    • Active pulmonary infections (such as bacterial pneumonia, fungal infections, active tuberculosis);

      • Having received radiotherapy or chemotherapy, which may affect the morphology or molecular results of distal lung tissue; ④ Combined severe immunodeficiency or long-term systemic therapy (such as ≥ 20 mg/d, More than 4 weeks);

        • Merge with other serious systemic diseases (such as advanced heart failure, end-stage renal disease), affecting study compliance or Survival expectation; ⑥ Pregnant or lactating women; ⑦ Refusing to sign the form or deemed unsuitable by the researcher to participate in the study.
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Observational model
Case-control
Time perspective
Prospective
Enrollment
20 participants (estimated)
Patient registry
No

Groups and cohorts

  • COPD(chronic hypoxia)

    Other: No intervention; observational biospecimen collection only

  • Normal(Normoxia)

    Other: No intervention; observational biospecimen collection only

Interventions

  • OtherNo intervention; observational biospecimen collection only

    No intervention; observational biospecimen collection only

06

What researchers measure

Primary outcomes

  1. Clarify the relationship between airway mucus embolism and secondary pulmonary fibrosis in COPD patients

    By comparing the distal lung tissue of patients undergoing COPD and non COPD lung cancer surgery, a systematic evaluation was conducted to determine the difference between airway mucus thrombus load and the degree of lung tissue fibrosis, and to answer whether airway mucus thrombus is an important pathological factor promoting secondary pulmonary fibrosis in COPD.

    Time frame: At the time of surgery and within 6 months after sample collection for laboratory analysis

Secondary outcomes

  1. The correlation between mucus plugs and clinical features

    Explore the relationship between mucus clot burden and clinical characteristics (such as smoking history, lung function, hypoxic status) and pathological indicators of patients. The association between mucus plugs and fibrosis molecular markers: Detect and compare epithelial mesenchymal transition (EMT) related molecules (E-cadherin, Vimentin), fibrosis markers (α - SMA, COL1A1), inflammatory markers, etc., to clarify the association between mucosal thrombus load and molecular level fibrosis response. Possible functions of Piezo1 channel: Preliminary exploration of the correlation between mucus clot load and Piezo1 expression and activity, providing clinical pathological evidence for revealing the role of mechanical pathways in mucus induced fibrosis.

    Time frame: At the time of surgery and within 6 months after sample collection for laboratory analysis

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Oct 2025 (actual). Primary completion is estimated for Jun 2026, 8 months after the start.

Of 60 observational studies under Pulmonary Fibrosis, half reached primary completion within 41 months of starting (the median), counting those still running; a quarter within 24 and three quarters within 111. This study's planned 8 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 14, 2025
First posted
Nov 19, 2025
StartActual
Oct 30, 2025
Primary completionEst.
Jun 30, 2026
CompletionEst.
Jun 30, 2026
Last update
Nov 19, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 19, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07236541
Lead sponsor
Ming Zhong
Responsible party
Ming Zhong (Chief Physician and Professor, Department of Pulmonary and Critical Care Medicine, Zhongshan Hospital, Fudan University, Shanghai Zhongshan Hospital) — Sponsor-investigator
First posted
Nov 19, 2025
Start date
Oct 30, 2025
Primary completion
Jun 30, 2026 (estimated)
Completion
Jun 30, 2026 (estimated)
Last update
Nov 19, 2025

Study contacts

shengyu hao
Contact
janet9yu@163.com
18359181031

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion